Quarterly report
Open the filing on sec.gov
AnaptysBio, Inc. (ANAB)
Nasdaq: ANAB · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2006
The companyfiscal 2025, as filed
Revenue$235M+157.0%
Net income-$13.2M+90.9%
Earnings per share$-0.44+91.1%
Operating cash flow$19.7M+114.6%
Cash$0.00-100.0%
Debtn/a
Shareholders’ equity$37.2M-47.5%
Shares, diluted30.2M+2.3%
Return on equityn/a
The recordfrom its filings
Filings in 2026113
Newest filingNov 12 · 10-Q
Annual reportSep 21, 2026
Quarterly reportNov 12, 2026
Next report due10-Q by Feb 14
Insider sales, 12 months$9.8M
Insider buys, 12 months$0.00
Patents granted21
Filer categoryNon-accelerated filer<br>Smaller reporting company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Results released
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Notice of intended sale
Open the filing on sec.gov
Annual report, transition period
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.